From: paul.dodd@usb.unibe.ch
Operating system: windows 2000
PHP version: 4.2.3
PHP Bug Type: Reproducible crash
Bug description: crash at if (preg_match('/(.|[\r\n])+/', $x)):
Crash also occurred with php version 4.3.1. Binary windows
version was used in both cases. Doe not occur for all
values of $x (probably only for very long strings ?).
<?php
$x = 'AN 11293237 20010507. AU Kraj, M.; Poglod, R.; Pawlikowski, J.; Maj,
S.; Nasilowska, B. IN Institute of Haematology and Blood Transfusion,
5 Chocimska Str., 00-957 Warsaw, Poland. TI Effect of pamidronate on
skeletal morbidity in myelomatosis. Part 1. The results of the first 12
months of pamidronate therapy. SO Acta Pol. Pharm. IS 0001-6837 YR 2000 VL
57 Suppl PG 113-116 LG English. DE ADULT; AGED; BONE-RESORPTION/PX
(psychology); CALCIUM/UR (urine); DIPHOSPHONATES/*TU (therapeutic
use); FEMALE; HUMAN; MALE; MIDDLE-AGE; MULTIPLE-MYELOMA/CO
(complications), *DT (drug therapy); OSTEOLYSIS/*PC (prevention &
control). RN 0 (Diphosphonates); 40391-99-9 (amidronate); 7440-70-2
(Calcium). AB BACKGROUND: Osteolytic bone destruction caused by
increase of osteolytic activity is a major manifestation of multiple
myeloma (MM) . Pamidronate
(3-amino-1-hydroxypropylidene)-1,1-bisphosphonate) inhibits
osteoclastic activity and reduces bone resorption. METHODS: Since
October 1995 the efficacy of pamidronate is evaluated in MM patients
all receiving anti-myeloma chemotherapy acc. to VMCP/VBAP
alternating regimen. 46 patients with stage III myeloma and
osteolytic lesions were randomized to receive either pamidronate
(Aredia; Novartis) 60 mg i.v. in 4-hour infusion monthly (n = 23) or
chemotherapy alone (control group n = 23). Estimation of performance
status, quality of life, pain score, analgesic consumption, serum
calcium concentration and twenty four-hours Calcium excretion, urine
Calcium/creatinine ratio is done at least once a month (before
pamidronate administration) while X-ray skeletal survey--before
treatment and then every six months. RESULTS: In the first months of
treatment apparent reduction of bone pain occurred. Hypercalcaemia
was revealed in 6 patients at entry into the study. In 5 of these
patients pamidronate restored and maintained normocalcaemia for a
median 6 months. In 3 patients an aggressive plasma cell
proliferation was accompanied by reoccurrence of hypercalcaemia. At
skeletal X-ray examination performed after 6 and 12 cycles of
pamidronate and by comparing each of consecutive imaging with
previous one the progression of osteolysis was respectively found in
67% and 39% of patients. In the control group corresponding figures
were: 79% and 70%. The mean number of skeletal events (pathologic
fracture, radiation to bone and spinal cord compression) per year was
lower in the pamidronate group (1.82) than in control-patients (2.72) ,
p 0.013. The proportion of patients who developed skeletal event
(excluding vertebral fractures) was lower in the pamidronate group
-34% v 52%. Adverse events of pamidronate: hypocalcaemia ( 2 mmol/l)
observed in 7 patients occurred in particular patients beginning from 2
to 7 days after drug administration. In 2 patients hypocalcaemia
that appeared in 24 hours after drug infusion was accompanied by
blood pressure decrease; in one case systolic blood pressure dropped
up to 60 mmHg, in the other one--to 90 mmHg. Muscular pain and fever
up to 39 degrees C (transient and self-limiting "influenza like
syndrom") occurred in 5 patients, in two patients after several hours
and in three other--after some dozens of hours from drug
administration. In one case hypertransaminasaemia was observed.
CONCLUSIONS: In the first year of treatment monthly intravenous
pamidronate administration as an adjunct to chemotherapy in patients
with advanced multiple myeloma with osteolysis is an efficient
approach in prevention and treatment of hyperacalcaemia,
hypercalciuria and bone pain. It also shows some preventive effect on
bone lesion occurrence. PT Clinical-Trial, Journal-Article,
Randomized-Controlled-Trial. ED 20010503.';
if (preg_match('/(.|[\r\n])+/', $x)):
$y = 1;
endif;
?>
--
Edit bug report at http://bugs.php.net/?id=19386&edit=1
--
Try a CVS snapshot: http://bugs.php.net/fix.php?id=19386&r=trysnapshot
Fixed in CVS: http://bugs.php.net/fix.php?id=19386&r=fixedcvs
Fixed in release: http://bugs.php.net/fix.php?id=19386&r=alreadyfixed
Need backtrace: http://bugs.php.net/fix.php?id=19386&r=needtrace
Try newer version: http://bugs.php.net/fix.php?id=19386&r=oldversion
Not developer issue: http://bugs.php.net/fix.php?id=19386&r=support
Expected behavior: http://bugs.php.net/fix.php?id=19386&r=notwrong
Not enough info: http://bugs.php.net/fix.php?id=19386&r=notenoughinfo
Submitted twice: http://bugs.php.net/fix.php?id=19386&r=submittedtwice
register_globals: http://bugs.php.net/fix.php?id=19386&r=globals